The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE), IgA nephropathy, and ...

The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE), IgA nephropathy, and ...

Tickling Wall Street’s already strong interest in the mechanism of action was Aurinia Pharmaceuticals Inc., which June 30 ...

Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement ...

Detailed price information for Aurinia Pharm Ord (AUPH-Q) from The Globe and Mail including charting and trades.

A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) and diabetes therapy, rilparencel. There were statistically significant ...

Vera Therapeutics Inc. (NASDAQ:VERA) is one of the best high short interest stocks with huge upside potential.

Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently ...